| Literature DB >> 23396710 |
Ang Li1, Pankaj Prasoon, Wu Hong, Hui Min Lu, Zhao Da Zhang, Zhang Zhaoda.
Abstract
The purpose of this analysis was to evaluate the technological viability, basic safety and consequence of central pancreatectomy (CP) with pancreaticogastrostomy in properly chosen sufferers with noncancerous central pancreatic pathology. This research is centered on the infirmary charts of West China hospital. We recruited 20 individuals from 2007 to 2009 diagnosed with benign cancerous growth of pancreatic body and neck. They underwent pancreatic body and neck resection adhering to pancreaticogastrostomy. We carried out central pancreatectomy following pancreaticogastrostomy in 20 patients: 8 with serous cyst adenomas, 11 with mucinous cystadenomas, and 1 with neuroendocrine tumor. The position of all tumors was restricted to body and neck of the pancreas, measuring a mean ± standard deviation of 2.6±1.3cm. The mean post-operative hospital stay was 7 days (ranging from 6 to 16 days).There was no intraoperative additional complications. From a technical perspective, CP is a safe and sound, pancreas-preserving pancreatectomy for non-enucleable non-cancerous pancreatic pathology restricted to the pancreatic body.Entities:
Keywords: Central Pancreatectomy; Pancreaticogastrostomy
Year: 2012 PMID: 23396710 PMCID: PMC3560545 DOI: 10.5812/ircmj.3112
Source DB: PubMed Journal: Iran Red Crescent Med J ISSN: 2074-1804 Impact factor: 0.611
Demographic data of all included patients
| Patients | Age | Gender | History | Main complaint | Pathology |
|---|---|---|---|---|---|
|
| 55 | M | Hypertension | Abdominal pain | Cystic neoplasm |
|
| 46 | F | Endometriosis | Abdominal pain | Cystic neoplasm |
|
| 47 | M | Hypertension/ Pneumonia | Pancreatitis | Cystic neoplasm |
|
| 73 | M | TCC/Afib/hypertension/CHF | Incidental | Cystic neoplasm |
|
| 48 | F | Hypertension/pneumonia | Pancreatitis | Cystic neoplasm |
|
| 73 | M | TCC/Afib a /hypertension/CHF | Incidental | Cystic neoplasm |
|
| 51 | F | Asthma/radiculopathy | Incidental | Cystic neoplasm |
|
| 50 | F | Gastroesophageal reflux disease | Incidental | Cystic neoplasm |
|
| 45 | M | Hypertension | Flank pain | Cystic neoplasm |
|
| 63 | F | Osteoarthritis/cholelithiasis | Back pain | Cystic neoplasm |
|
| 38 | M | None | Incidental | Cystic neoplasm |
|
| 67 | F | Asthma/COPD | Incidental | Cystic neoplasm |
|
| 68 | M | Gastro esophageal reflux disease | Incidental | Cystic neoplasm |
|
| 71 | M | Abdominal pain | Incidental | Cystic neoplasm |
|
| 68 | M | Hypertension | Incidental | Cystic neoplasm |
|
| 59 | M | Abdominal pain, Anxiety | Incidental | Cystic neoplasm |
|
| 46 | F | Abdominal pain, vomiting | Incidental | Cystic neoplasm |
|
| 54 | F | Osteoarthritis/cholelithiasis | Back pain | Cystic neoplasm |
|
| 65 | M |
Hypertension, CCF | Incidental | Cystic neoplasm |
|
| 59 | M | Abdominal pain | Incidental | Cystic neoplasm |
aAbbreviations: A fib: Atrial fibrillation; CAD: coronary artery disease; CCF: congestive cardiac failure
Figure 1Picture illustrating the pancreatic stent passing through the post. Abdominal wall. Stent had been placed to the main pancreatic duct to prevent leakage from anastomotic site and keep patency of pancreatic juice to the stomach
Operative characteristics of all patients
| Patients | Incision Choice | Anesthesia Time(mins) median | Operation Time(mins) median | Blood Loss(ml) median | Size of Re section(cm) median | Tumor Size(cm) median | Tumor Pathology |
|---|---|---|---|---|---|---|---|
|
| LSC | 230 | 170 | 755 | 14.5 | 1.2 | Serous oligocystic adenoma |
|
| Midline | 240 | 185 | 690 | 12.6 | 1.0 | Mucinous cystadenoma |
|
| Midline | 255 | 210 | 735 | 11.7 | 1.1 | Serous microcystic adenoma |
|
| Midline | 245 | 205 | 640 | 43.8 | 3.2 | Mucinous cystadenoma |
|
| Midline | 260 | 220 | 705 | 38.6 | 2.9 | Serous microcystic adenoma |
|
| LSC | 255 | 190 | 800 | 44.8 | 3.6 | Neuroendocrine/glucagonoma |
|
| Midline | 250 | 215 | 650 | 30.8 | 2.9 | Mucinous cystadenoma |
|
| Midline | 310 | 270 | 900 | 49.5 | 3.4 | Mucinous cystadenoma |
|
| Midline | 280 | 235 | 995 | 50.6 | 4.0 | Mucinous cystadenoma |
|
| Midline | 265 | 220 | 755 | 47.3 | 3.8 | Mucinous cystadenoma |
|
| LSC | 215 | 175 | 680 | 15.6 | 1.7 | Serous oligocystic adenoma |
|
| Midline | 310 | 275 | 1050 | 85.3 | 5.3 | Serous microcystic adenoma |
|
| Midline | 295 | 250 | 895 | 63.9 | 5.0 | Serous microcystic adenoma |
|
| Midline | 310 | 270 | 765 | 45.7 | 3.9 | Mucinous cystadenoma |
|
| LSC | 355 | 310 | 1100 | 69.4 | 4.3 | Mucinous cystadenoma |
|
| Midline | 380 | 340 | 1060 | 70.5 | 5.6 | Serous microcystic adenoma |
|
| Midline | 354 | 305 | 900 | 39.2 | 3.2 | Serous microcystic adenoma |
|
| Midline | 340 | 295 | 980 | 37.9 | 3.0 | Mucinous cystadenoma |
|
| Midline | 265 | 210 | 865 | 43.9 | 3.6 | Mucinous cystadenoma |
|
| Midline | 270 | 224 | 700 | 22.8 | 1.8 | Mucinous cystadenoma |
Figure 2Post-operative follow-up CTscan showing the stent which had been placed to the main pancretic duct and anastomosed to the gastic wall